| http://www.w3.org/ns/prov#value | - BEVERLY, MA--(Marketwire - Dec 24, 2012) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today provides commentary on a front page New York Times article published December 23, 2012 titled, Genetic Gamble; New A
|
